AML in remission: discussing consolidation and transplantation

Hearing that acute myeloid leukaemia (AML) is in remission is an important milestone. It also creates a new planning question: what treatment or monitoring comes next, and why? A normal-looking blood test is not enough to choose between a proposed consolidation programme and a transplant assessment.

Ask what the remission statement is based on

The NCI describes induction and consolidation as distinct phases of AML treatment. Consolidation addresses disease that may remain after the initial response. Ask the haematologist to identify the marrow report, blood results and any molecular or residual-disease assessment used to describe the current response. Record the date of each test. “In remission” copied from an old discharge letter may not describe the situation today.

Request the exact wording of the response assessment rather than converting it into a personal probability of cure. If one report mentions measurable residual disease and another does not, ask whether the methods and time points differ. Do not infer that a missing result is negative.

Prepare the decision file

• The original marrow diagnosis and complete genetic or molecular reports.
• Details of induction therapy, with dates and major complications.
• The marrow and laboratory reports used to assess response.
• The current doctor’s proposed next phase and its intended start date.
• Any completed donor or transplant assessment, clearly separated from tests that are only planned.

This is a focused handover, not a request to repeat every investigation. Ask the receiving team to state what additional information would actually change its recommendation.

Separate referral from a commitment to transplant

A transplant consultation evaluates whether a particular transplant strategy is appropriate; booking it does not establish eligibility. Ask how the specialist weighs the disease findings, treatment response, other health conditions and available alternatives. If a donor search is proposed, request an explanation of how it fits the treatment timetable.

A useful written opinion should make the branches clear: what is recommended now, what must be checked first, and which later result could lead to a different plan. If two centres disagree, ask each to address the same clinical facts. One may have reviewed a response report that the other has not yet received.

Protect the interval between treatment phases

Before considering travel to Turkey, ask the current team how urgent the next decision is and whether transfer is medically appropriate. Obtain a plan for blood tests, transfusion support if prescribed, and clinical contact while the review is pending. Do not postpone an already recommended phase simply because a consultation date is available abroad.

For budgeting, distinguish consultation and additional assessment from consolidation treatment, donor work and transplant admission. Ask when the estimate can become more definite and what remains conditional. This prevents a preliminary transplant price from being mistaken for the cost of the entire next stage.

At the end of the consultation, request a short written explanation you can share with the current haematologist: the recommended next step, its reason, the information still needed and the clinician responsible for the next checkpoint. This guide supports that discussion; it cannot determine the correct treatment after remission for an individual patient.

A practical next step

For the practical arrangements, see What to check in a bone marrow transplant cost estimate.

Sources

• NCI: Acute Myeloid Leukemia Treatment